GlassScriptPhysician profile
Brianne Frascella
NPI 1407437023
$3,810.73
in general payments reported to CMS, 2019-2025
27 companies · $729 in 2025
The $729 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $95.86 · 2022: $521 · 2023: $1,249 · 2024: $1,215 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,193.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $895.04 | 2023-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $830.40 | 2022-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $313.94 | 2022-2024 | Opsumit, Uptravi |
| Novartis Pharmaceuticals Corporation | $246.98 | 2022-2025 | |
| Glaxosmithkline, LLC. | $192.16 | 2022-2024 | Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $188.17 | 2022-2023 | Farxiga, Brilinta |
| Medtronic, INC. | $157.38 | 2025 | Selectsecure |
| Vifor Pharma, INC. | $149.73 | 2023-2024 | Veltassa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.83 | 2022-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $104.67 | 2021-2024 | Camzyos |
| Merck Sharp & Dohme LLC | $73.97 | 2022-2023 | Verquvo |
| Biotronik INC. | $64.45 | 2025 | Acticor 7 Vr-T Dx, Amvia Edge |
| Daiichi Sankyo INC. | $59.87 | 2022-2023 | Injectafer |
| Kiniksa Pharmaceuticals International, Plc | $54.42 | 2024 | Arcalyst |
| Pulmonx Corporation | $46.32 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $41.37 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.28 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.30 | 2022 | |
| Heartflow, INC. | $36.21 | 2025 | |
| Abbvie INC. | $31.03 | 2021 | |
| Edwards Lifesciences Corporation | $19.41 | 2025 | Pascal |
| Biohaven Pharmaceutical Holding Company LTD. | $15.36 | 2022 | |
| Alnylam Pharmaceuticals INC. | $14.94 | 2025 | Onpattro |
| Pfizer INC. | $14.65 | 2022 | |
| Paratek Pharmaceuticals, INC. | $14.37 | 2024 | Nuzyra |
| Amgen INC. | $13.63 | 2024 | Repatha |
| Kiniksa Pharmaceuticals, LTD. | $12.85 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brianne Frascella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.